Autopsy report · NCT02559024
Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer
Cause of deathStaffing, sites or logistics, also drug or device supply
“Drug expired and access to additional supply ended. PI left the institution shortly afterwards and the study will not be re-activated. Only 4 patients were enrolled.”
Life of this trial
- Registered 6 months before it started.
- Ran for about 2 years 7 months before it stopped.
- 4 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Providence Health & Services
- Sponsor type
- University, hospital or other
- Conditions
- Colorectal Neoplasms
- Interventions
- MEDI6469
- Participants
- 4
- Sites
- 1
- Countries
- United States
Trials that died the same way
- HIV-1 Vaccine Test in Uninfected Adult Volunteers
“The study product was revised. PI withdrew the study without enrolling participants..” - Potential Benefits of Sleeve Gastrectomy Surgery on Diabetic Gastroparesis Symptoms
“No participants enrolled. Study terminated at PI's discretion” - Superficial Cervical Plexus Block for Improved Outcomes in Pediatric Otolaryngologic Surgery
“The current PI is leaving the study. Study team is awaiting FDA PI change approval.” - CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
“Study drug no longer available” - Dual Antiplatelet Therapy Adherence With Reminder App Usage
“The PI is discontinuing the study since the platform/Application is no longer available for use. Study terminated effective 7/29/2024.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.